IMPORTANCE Information on the incidence of central serous chorioretinopathy (CSC) in individuals who receive corticosteroids is scarce but clinically important because these agents are useful and widely used.
C entral serous chorioretinopathy (CSC) is one of the most common vision-threatening retinopathies, after agerelated macular degeneration, diabetic retinopathy, and retinal vein occlusion. 1 Many clinical studies have documented the characteristics of CSC in detail, including the higher incidence in men and the difference in incidence between elderly and middle-aged individuals. 2 However, information on incidence is very scarce, with only 2 population-based studies reported to date. One study is from Olmsted County, Minnesota, 3 and included only 74 cases, and the other is based on Taiwanese insurance data. 4 The association of CSC with use of corticosteroids is well known. One case-control study revealed that use of corticosteroids increased the risk of CSC, with an odds ratio of 37. 5 However, there is a lack of information on incidence, and the only published estimation of the incidence of CSC among persons taking corticosteroids (4.4 per 10 000 person-years) is based on Taiwanese insurance claims. 6 Corticosteroids are used for long periods in some patients; therefore, we wanted to estimate the risk of CSC according to whether patients are past users, recent users, or long-term users of corticosteroids. Corticosteroids are useful agents, so information on the incidence of CSC among users of these medications would be clinically informative. The South Korean National Health Insurance Service (NHIS) is a good source of data on CSC in the general population as well as in corticosteroid users.
Methods
This nationwide cohort study was approved by the institutional review board of Severance Hospital, Yonsei University College of Medicine, and adhered to the tenets of the Declaration of Helsinki. The requirement for informed consent was waived in view of the retrospective design of the study and the deidentified nature of the data.
Database
The Korean NHIS initially developed a nationally representative sample of 1 million persons for research purposes in 2014. include improved integrity and reliability because of data cleaning; a relatively long study duration, including 14 years of follow-up; improved representativeness using a more detailed 2142 sampling stratum (the product of categories defined by age [ 
Participants and Central Serous Chorioretinopathy
The NHIS-NSC 2002-2015 provided data on each diagnostic code to 1 decimal place (eg, H35.7) in the period 2002 through 2010 and up to 2 decimal places (eg, H35.70) in 2011 through 2015. The most recent (seventh) edition of the Korean Classification of Diseases, which corresponds to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), was applied from January 2011, so the NHIS database has stored the information at a lower hierarchical level and with specific diagnostic codes since then. Therefore, in this database, only the H35.7 diagnostic code (which indicates "separation of retinal layers") is available before January 2011, and the lower hierarchical and specific diagnostic code of H35.70 (which indicates "central serous chorioretinopathy") is available after this date. Incident cases of CSC are defined as patients who visited an ophthalmologist and received a diagnostic code of H35.70 (CSC) at least once. 4 Patients who received a diagnostic code of H35.7 (separation of retinal layers) in 2002 through 2010 were not included in this study to exclude chronic or recurrent cases. Data were included in the study for individuals 20 years or older, who were enrolled in the NHIS between 2011 and 2015, and were followed up from January 1, 2011 (the index date), until the date of the first documentation of loss to follow-up because of disqualification by the NHIS (usually death) or until a diagnosis of CSC. The primary end point of the study was the incidence of CSC. For incidence estimates, the date of the earliest claim with the diagnostic code of CSC was defined as the event date.
Corticosteroid Exposure
Information on all types of corticosteroids used from 2002 through 2015 was identified, including formulation and route of administration, including topical application. To distinguish between past and recent or current use, the exposure period was divided into 3 groups (ie, corticosteroid use from 2002  through 2005, from 2006 through 2009, and from 2010  through 2015) . These 3 groups were divided into 8 subgroups ( Figure) . More detailed information about the corticosteroid formulations and doses used is in the eMethods and eTables 1 to4intheSupplement.
Key Points
Question What is the incidence of central serous chorioretinopathy (CSC) among patients who have ever used corticosteroid and those who have never used it, based on a national sample cohort in South Korea?
Findings In this population-based cohort study, 5-year incidence of CSC per 10 000 person-years was 3.5 in the general population, 2.5 among those who had never used corticosteroids, and 3.6 among those who had ever used corticosteroids. The incidence was higher in men and those aged 40 to 49 years.
Meaning These findings provide additional evidence that corticosteroid use increases the risk of CSC; however, the risk ratio in this study was less than that previously reported.
Statistical Analysis
The 5-year incidence of CSC per 10 000 person-years in adults 20 years and older was estimated by dividing the number of patients with a diagnosis of CSC by the total number of personyears of follow-up. A Cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with the 95% CI in the comparison between groups of corticosteroid users in the different study periods. The model was adjusted for age, sex, income level (10 strata), and residential area (16 regions). Prevalence was also estimated (eTable 5 in the Supplement). All P values were 2-sided, and those less than .05 were considered significant. The statistical analyses were performed using SAS version 9.4 (SAS Institute Inc) and Stata/MP version 14.0 (StataCorp).
Results
Incidence of CSC 3-3.6) per 10 000 person-years (5.4 for men and 1.6 for women). The ratio of cases in men to cases in women was 3.4. Table 2 shows the incidence of CSC according to age group. The incidence was highest among the overall group aged 40 to 49 years (5.5 per 10 000 person-years) and in men aged 40 
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Association of Corticosteroid Use With Incidence of Central Serous Chorioretinopathy in South Korea to 49 years (8.7 per 10 000 person-years). In women, the incidence was highest in the group aged 50 to 59 years (2.4 per 10 000 person-years). The ratio of cases in men to cases in women was 4.4 and 4.1 in those in the age groups 30 to 39 years and 40 to 49 years, respectively.
Incidence of CSC According to Corticosteroid Use Table 3 shows the incidence of CSC in those who had ever used corticosteroids and those who had never used corticosteroids. Some form of corticosteroid therapy was documented to have been used at least once in 783 099 individuals in the total cohort of 868 939 individuals (90.1%) during the 14-year study period. In 2002 through 2015, 372 292 of 431 908 men (86.2%) and 410 807 of 437 031 women (94.0%) were identified to have ever used corticosteroids. The incidence of CSC was 3.6 per 10 000 person-years (5.7 in men vs 1.6 in women) among those who had ever used corticosteroids, and 2.5 per 10 000 person-years (3.0 in men vs 1.2 in women) among those who had never used corticosteroids. The incidence of CSC was lowest overall in women who did not use corticosteroids. The highest incidence was observed in male individuals aged 40 to 49 years who had ever used corticosteroids (9.4 per 10 000 person-years); the incidence in men of the same age without a history of corticosteroid use was almost half of that value (4.9 per 10 000 person-years). The 
Prevalence
The prevalence data are summarized in eTable 5 in the Supplement. The prevalence in 2011 through 2015 was 6.1 per 10 000 persons (9.4 in men vs 3.0 in women). The annual prevalence per 10 000 persons gradually increased from 5.5 in 2011 to 7.3 in 2015.
Discussion
The present study estimates that the population-based incidence of CSC is 3.5 per 10 000 person-years in the general Ko- 6 in women) . Surprisingly, more than 90% of adults had been prescribed some form of corticosteroid therapy in the 14 years from 2002 through 2015. The incidence of CSC was lower in adults who had never used corticosteroids (2.5 per 10 000 person-years) and higher in those who had ever used corticosteroids (3.6 per 10 000 personyears). This estimated difference in the incidence rate had an adjusted HR of 1.81 (95% CI, 1.47-2.23). Two other studies have focused on the incidence of CSC using a population-based sample. The study based on a medical record review of patients in Olmsted County from 1980 to 2002 reported an annual incidence of 1.0 (95% CI, 0.7-1.2) in 10 000 men and 0.2 (95% CI, 0.1-0.3) in 10 000 women, giving a total of 74 cases of CSC. 3 This figure is lower than that in our study, which may reflect the fact that the Olmsted County study included a predominantly white population, whereas the sample in this study was Korean. That study failed to show the association of CSC with corticosteroid use; however, as noted by the authors in the limitation section of their report, 74 cases of CSC is too small to constitute a representative sample. The other study was based on Taiwanese insurance data from 2001 to 2006 and reported an annual incidence of CSC of 2.1 per 10 000 adults aged 20 to 64 years with no history of corticosteroid use (2.7 per 10 000 men vs 1.5 per 10 000 women). 4 In the present study, the incidence was 2.5 per 10 000 personyears in those who had never used corticosteroids (3.0 in men vs 1.2 in women; Table 3 ). The slightly higher incidence of CSC in South Korea may reflect better access to medical care and more use of corticosteroids in this country; alternatively, it may simply reflect an actual increase in incidence over the past decade. Consistent with the Taiwanese report, CSC occurred most frequently in male individuals aged 35 to 39 years who had ever used corticosteroids, with a peak incidence of 4.9 per 10 000 person-years in the Korean study and 4.4 per 10 000 personyears in the Taiwanese study. 4 The association between CSC and corticosteroid exposure has been widely reported in the literature.
6,10-17 Of 412 035 users of oral corticosteroids who were followed up from 2000 to 2008 in the Taiwan study, 320 cases of CSC were documented, and the incidence rate was 4.4 per 10 000 personyears (5.5 in men and 3.4 in women). 6 In the present study, the incidence rate of CSC was 3.6 per 10 000 person-years in corticosteroid users overall (5.7 in men and 1.6 in women; Table 3 ). In the Taiwanese study, corticosteroid use was defined as an oral corticosteroid having been prescribed at least twice in 2 consecutive months, whereas in the present study, the status of having ever used corticosteroids was defined as use of any type of corticosteroid by any route in 2002 through 2015. Therefore, the lower incidence of CSC in our study may reflect a less stringent definition of corticosteroid use (including, for example, one-time use of a topical corticosteroid cream) than that in the Taiwanese study. 6 One retrospective, multicenter case-control study that reported on 312 patients with CSC (including 45 in patients who had used corticosteroids) and 312 control participants (selected patients with differing ophthalmologic conditions, including 5 corticosteroid users) estimated the risk of CSC associated with corticosteroid use, and ultimately reported an odds ratio of 37.1 (95% CI, 6.2-221.8) 5 ; however, this wide CI implies an insufficient number of cases in their analysis. The researchers performing the aforementioned study acknowledged the major limitation of using a retrospective approach, because physicians evaluating patients with CSC are more likely to ask about corticosteroid use because of its well-known association with this health condition. The incidence of CSC among corticosteroid users in South Korea and Taiwan suggests that the figure reported in that study is an overestimate.
Our findings showed that the prior use of corticosteroids also significantly increased the risk of the future development of CSC (Figure) . However, we believed it was necessary to critically analyze this interpretation because of the relatively few cases of CSC reported among former users; there were 35, 58, and 46 CSC cases among individuals in the corticosteroid 
Limitations
Several limitations should be taken into consideration when interpreting the results of this study. Diagnoses based on the Korean Standard Classification of Diseases may be less accurate than those obtained using some of the other standardized procedures. Misclassification is also possible. However, crosssectional epidemiologic studies of CSC would be very difficult to perform because of the transient nature of the disease and the inability to identify it after recovery.
Studies based on medical record review as well as claims data suffer from the possibility of underestimation. A claimsbased study may not be the most accurate way of investigating the incidence of this episodic disease but may still provide a reasonable estimation of the association of CSC with the use of corticosteroids. A more accurate analysis of the various routes of administration and formulations of corticosteroids used is needed. However, as mentioned in the eMethods in the Supplement, it is difficult to analyze the use of corticosteroids prospectively because of the real-world complexities involved.
It would also be ideal to evaluate the association with various other diseases; however, this goes beyond the scope of this study. Lastly, the limitations of this study include the possibility that ethnic differences may exist among individuals of non-South Korean ethnic groups.
Conclusions
This retrospective population-based cohort study investigated the incidence of CSC in the South Korean population and found an incidence of 3.5 cases per 10 000 person-years in the total population, with rates of 2.5 per 10 000 person-years in those who had never used corticosteroids and 3.6 per 10 000 person-years in those who had ever used corticosteroids. Use of corticosteroids was clearly associated with an increased risk of CSC; the likelihood of developing CSC was affected not only by recent use but also by earlier use (although future observational studies are required to determine a potential increased recency effect, by which a more recent history of corticosteroid use carries a greater risk than more remote exposure to corticosteroids). When 10 000 people were followed up for 1 year, CSC was diagnosed in as many as 4 patients who had used corticosteroids (3.6 [95% CI, 3.4-3.8]) and in as many as 3 who had not (2.5 [95% CI, 3.0-3.0]). The most vulnerable group was men aged 40 to 49 years, in whom the incidence of CSC was approximately 5 per 10 000 person-years among those who had never used corticosteroids and up to 10 (ie, approximately 1 per 1000 person-years) in those who had ever used corticosteroids. In women, the incidence of CSC per 10 000 person-years was 1.2 among those who had never used corticosteroids and 1.6 among those who had ever corticosteroids, with the risk increasing to up to 3 per 10 000 person-years in female corticosteroid users aged 50 to 59 years. It is important to be able to provide patients with accurate information about the adverse effects of corticosteroids.
Overall, approximately 4 new cases per year of CSC per 10 000 people who had ever used corticosteroid is considerably less than the risk ratio previously reported. Corticosteroids are widely used, so it is clinically helpful to have an appreciation of the incidence of CSC in patients taking these agents. The Korean National Health Insurance Service (KNHIS) controls all medical costs accrued by beneficiaries, medical providers, and the government. Therefore, almost all medical data (including diagnostic codes, prescription drugs, procedures performed, and personal information) are centralized in large databases. The KNHIS and medical providers exchange all cost-related healthcare information using electronic codes of the Korean electronic data interchange (KEDI) (e.g., the KEDI code for "Visual Field Examination [Automated]" is E6691, and for "Cosopt; Merck and Co., Inc." is 655500390 [E09060211]). Each South Korean resident is assigned a unique identification number at birth, and this number is used by the KNHIS to identify each individual. Thus, health care claims data are not omitted or duplicated. Moreover, the currently used second version of NHIS-National Sample Data was developed for research purposes, resulting in improved integrity and reliability of the data following data cleansing by NHIS. Therefore, we believe that the drug information included in our study is highly accurate.
Drug exposure is difficult to analyze using claims data. In a previous Taiwanese study, steroid exposure was defined as repeated prescriptions for any steroid administered by the oral route in 2 consecutive months. From the data in Figure 1 in the main manuscript, it is difficult to evaluate the risk of central serous chorioretinopathy (CSCR) with recent steroid use only because former use also affects the incident CSCR. For example, the risk of CSCR has actually risen due to past intravenous use, which can be misinterpreted as having been caused by recent topical use.
There are methods for drug analysis in the clinical setting. However, in a retrospective case-control study, it is difficult to control surveillance bias when we are using claims data. To prospectively analyze as much data as possible, we searched for steroid use according to route of administration between 2002 and 2010 and summarize our findings in eTable 1. The incidence and hazard ratio for the incidence of CSCR since 2011 are estimated. This analysis assumes that the patterns of steroid use until 2010 will be similar to those after 2010. This is inaccurate; however, it is still useful for determining the overall association. The information on steroid use was identified based on dosage forms (oral administration, topical application, injections or parenteral preparations, and eye drops) and type of corticosteroid, including fludrocortisone, betamethasone, dexamethasone, methylprednisolone, triamcinolone, prednisolone, prednisone, hydrocortisone, and cortisone. eTable 1 shows the risk of CSCR according to the dosage form. In terms of route of administration, no association (adjusted hazard ratio [HR] 1.01) was observed between use of steroid eye drops and CSCR, and a borderline association (adjusted HR 1.30, 95% confidence interval [CI] 0.96-1.77) was observed between topical application only and CSCR. The risk of CSCR increases in subjects who took a steroid orally, which is the most common route (adjusted HR 1.37, 95% CI 1.16 -1.62) and in subjects who took oral steroids orally and used them topically (adjusted HR 1.44, 95% CI 1.22-1.69). The incidence of CSCR was highest among individuals who have been used steroids via injection or parenteral steroid preparations at least once (7.0 cases of CSCR per 10,000 person-years, 95% CI 3.2-15.6). However, the wide CI indicates a less precise finding.
In order to evaluate the dose-dependent association between steroid use and CSCR, we extracted never steroid users and oral only steroid users from the data (n=394,791). eTable 2 shows the incidence of CSCR according to amount of oral steroid administration. A trend of increasing HR values for cases of CSCR with increasing dose of prednisolone or an equivalent dose was observed
In our main paper, the classification shows that the incidence of CSCR is relatively high in individuals who used steroids between 2010 and 2015 (HR, minimum 1.54, maximum 2.15 in eTable 1), and some subjects used steroids after development of CSCR. Therefore, the actual effect may be greater than this.
In conclusion, the use of steroids in the real world is very complex in terms of type, route, and duration. Therefore, it is difficult to precisely define steroid exposure in the real world and compare the incidence of CSCR in each defined subgroup. Based on the assumption that past patterns of use persist in the future, we searched for steroid use from 2002 to 2010, and the data obtained show that the risk of CSCR is highest among those who received intravenous corticosteroids at least once. This analysis is based on an arbitrary assumption, so caution is needed when interpreting this finding.
To evaluate the rationale behind the prescription of corticosteroids, we examined the medical departments prescribing the medications and the diagnoses of individuals receiving corticosteroids using an explorative analysis for all claims in 2002. A total of 808,199 claims were filed for the prescription of corticosteroids out of a total of 5,194,582 claims from 979,390 subjects. More than 50% of corticosteroids were prescribed by the departments of internal medicine or dermatology (eTable 3). A total of 3,194 diagnoses were included, with the 30 most frequent diagnoses provided in eTable 4.
We defined prevalent cases as those with least one eye clinic visit per calendar year. Thus, this approach considered uveitis as an episodic CSCR rather than a chronic disease. This conservative definition of prevalence includes patients who might need a check-up for CSCR or other ophthalmic problems each calendar year, and thus might be informative for ophthalmologists. To include all patients with CSCR based on this approach, we included patients diagnosed with CSCR from 2011 to 2015. The annual prevalence was calculated based on the total number of cases per year and the total population that qualified for NHIS-NSC on the first day of January of each year. Period prevalence and annual prevalence per 10,000 persons were estimated during 2011-2015 (eTable 5 
